BryoLogyx Inc., (www.BryoLogyx.com), a privately-held, pre-clinical company developing a new class of proprietary drugs to enhance the response rates and treatment durability of cancer immunotherapies, announced today that the Company has named William Grossman, M.D., Ph.D., to its Board of Directors
May 28, 2019
· 3 min read